144 related articles for article (PubMed ID: 35687724)
1. IgG-Binding Nanobody Capable of Prolonging Nanobody-Based Radiotracer Plasma Half-Life and Enhancing the Efficacy of Tumor-Targeted Radionuclide Therapy.
Hu B; Liu T; Li L; Shi L; Yao M; Li C; Ma X; Zhu H; Jia B; Wang F
Bioconjug Chem; 2022 Jul; 33(7):1328-1339. PubMed ID: 35687724
[TBL] [Abstract][Full Text] [Related]
2. High in-vivo stability in preclinical and first-in-human experiments with [
Qin X; Guo X; Liu T; Li L; Zhou N; Ma X; Meng X; Liu J; Zhu H; Jia B; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):302-313. PubMed ID: 36129493
[TBL] [Abstract][Full Text] [Related]
3. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking.
Li L; Liu T; Shi L; Zhang X; Guo X; Hu B; Yao M; Zhu H; Yang Z; Jia B; Wang F
Theranostics; 2022; 12(12):5551-5563. PubMed ID: 35910795
[No Abstract] [Full Text] [Related]
4. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
[No Abstract] [Full Text] [Related]
5. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
[TBL] [Abstract][Full Text] [Related]
6. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
[TBL] [Abstract][Full Text] [Related]
7. In vivo detection of small tumour lesions by multi-pinhole SPECT applying a (99m)Tc-labelled nanobody targeting the Epidermal Growth Factor Receptor.
Krüwel T; Nevoltris D; Bode J; Dullin C; Baty D; Chames P; Alves F
Sci Rep; 2016 Feb; 6():21834. PubMed ID: 26912069
[TBL] [Abstract][Full Text] [Related]
8. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
Evazalipour M; D'Huyvetter M; Tehrani BS; Abolhassani M; Omidfar K; Abdoli S; Arezumand R; Morovvati H; Lahoutte T; Muyldermans S; Devoogdt N
Contrast Media Mol Imaging; 2014; 9(3):211-20. PubMed ID: 24700748
[TBL] [Abstract][Full Text] [Related]
9. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
D'Huyvetter M; Vincke C; Xavier C; Aerts A; Impens N; Baatout S; De Raeve H; Muyldermans S; Caveliers V; Devoogdt N; Lahoutte T
Theranostics; 2014; 4(7):708-20. PubMed ID: 24883121
[TBL] [Abstract][Full Text] [Related]
10. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
11. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of [
Liu T; Wu Y; Shi L; Li L; Hu B; Wang Y; Gao H; Yu X; Zhang X; Zhao H; Wan Y; Jia B; Wang F
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1810-1821. PubMed ID: 35013776
[TBL] [Abstract][Full Text] [Related]
13. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
[TBL] [Abstract][Full Text] [Related]
14. Novel Radiolabeled TMTP1 for Long-Acting Hepatocellular Carcinoma Therapeutics.
Yao L; Wen X; Guo W; Fang J; Zhang X; Guo Z; Huang J; Li Y
Mol Pharm; 2022 Sep; 19(9):3178-3186. PubMed ID: 35972772
[TBL] [Abstract][Full Text] [Related]
15. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
Müller C; Struthers H; Winiger C; Zhernosekov K; Schibli R
J Nucl Med; 2013 Jan; 54(1):124-31. PubMed ID: 23236020
[TBL] [Abstract][Full Text] [Related]
16. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.
Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Lyerly HK; Zalutsky MR
J Nucl Med; 2014 Apr; 55(4):650-6. PubMed ID: 24578241
[TBL] [Abstract][Full Text] [Related]
17. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
18. Improved in Vivo Targeting Capability and Pharmacokinetics of
Gao H; Luo C; Yang G; Du S; Li X; Zhao H; Shi J; Wang F
Bioconjug Chem; 2019 Jul; 30(7):2038-2048. PubMed ID: 31063685
[TBL] [Abstract][Full Text] [Related]
19. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression.
Huang L; Gainkam LO; Caveliers V; Vanhove C; Keyaerts M; De Baetselier P; Bossuyt A; Revets H; Lahoutte T
Mol Imaging Biol; 2008; 10(3):167-75. PubMed ID: 18297364
[TBL] [Abstract][Full Text] [Related]
20. In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT.
Vaneycken I; Govaert J; Vincke C; Caveliers V; Lahoutte T; De Baetselier P; Raes G; Bossuyt A; Muyldermans S; Devoogdt N
J Nucl Med; 2010 Jul; 51(7):1099-106. PubMed ID: 20554727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
